-
Signature
-
/s/ Douglas Barry, Attorney-in-Fact
-
Issuer symbol
-
KNSA
-
Transactions as of
-
08 Jan 2026
-
Net transactions value
-
-$502,680
-
Form type
-
4
-
Filing time
-
09 Jan 2026, 16:35:42 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
C/O KINIKSA PHARMACEUTICALS INTERNATIONA, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM |
/s/ Douglas Barry, Attorney-in-Fact |
09 Jan 2026 |
0001835458 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
KNSA |
Class A Ordinary Share |
Sale |
$502,680 |
-12,000 |
-39% |
$41.89 |
19,086 |
08 Jan 2026 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: